Aspergillus Antibodies by Complement Fixation
Also known as: ASPER
Use
This test is used in aiding the diagnosis of allergic bronchopulmonary aspergillosis (ABPA) and aspergilloma. It is recommended that immunodiffusion be performed in parallel with complement fixation for a more comprehensive serologic assessment. This test can help differentiate between Aspergillus infections and other dimorphic fungi due to the common cross-reactions seen within the Aspergillus genus.
Special Instructions
Parallel testing is preferred for the assessment, and convalescent specimens must be received within 30 days from receipt of the acute specimens. Specimens should be marked as 'acute' or 'convalescent' for accurate testing and interpretation.
Limitations
Cross-reactions with dimorphic fungi are not unusual within the genus Aspergillus, which may lead to potential false positives. The test does not specifically diagnose invasive aspergillosis. For such cases, ordering Aspergillus Galactomannan Antigen by EIA, Serum (0060068) or Aspergillus Galactomannan Antigen by EIA, Bronchoscopy (2003150) is advised. Complement fixation may not detect low-level antibodies.
FDA ApprovedNew York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 5053-4
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.4 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection. Transfer serum into ARUP Standard Transport Tube. Mark specimens plainly as 'acute' or 'convalescent.'
Causes for Rejection
Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |